Elucidating the exact pharmacological system of motion (MOA) of naturally transpiring compounds can be difficult. Although Tarselli et al. (60) made the 1st de novo artificial pathway to conolidine and showcased this naturally developing compound efficiently suppresses responses to equally chemically induced and inflammation-derived pain, the pharm